{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:21:40Z","timestamp":1781511700271,"version":"3.54.1"},"reference-count":47,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,6,20]],"date-time":"2016-06-20T00:00:00Z","timestamp":1466380800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine associations between exposure to various subgroups of antipsychotic drugs and risk of hip fracture in older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Nationwide cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Norway, 2005\u20132010.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Everyone living in Norway born before 1945 (N\u00a0=\u00a0906,422).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>\n                      Information was obtained on all prescriptions of antipsychotic drugs dispensed from 2004 to 2010 (Norwegian Prescription Database) and data on all primary hip fractures from 2005 to 2010 (Norwegian Hip Fracture Registry). Incidence rates of hip fracture during person\u2010time exposed and unexposed to antipsychotic drugs were compared by calculating the standardized incidence ratio (\n                      <jats:styled-content style=\"fixed-case\">SIR<\/jats:styled-content>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty\u2010nine thousand nine hundred thirty\u2010eight (4.4%) participants experienced a primary hip fracture. Greater risk of hip fracture was associated with exposure to any antipsychotic (\n                      <jats:styled-content style=\"fixed-case\">SIR<\/jats:styled-content>\n                      \u00a0=\u00a02.1, 95% confidence interval (\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      )\u00a0=\u00a01.9\u20132.1), first\u2010generation antipsychotics (\n                      <jats:styled-content style=\"fixed-case\">SIR<\/jats:styled-content>\n                      \u00a0=\u00a02.0, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      \u00a0=\u00a01.8\u20132.2), second\u2010generation antipsychotics (\n                      <jats:styled-content style=\"fixed-case\">SIR<\/jats:styled-content>\n                      \u00a0=\u00a02.2, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      \u00a0=\u00a01.9\u20132.4), prolactin\u2010sparing antipsychotics (\n                      <jats:styled-content style=\"fixed-case\">SIR<\/jats:styled-content>\n                      \u00a0=\u00a02.4, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      \u00a0=\u00a01.8\u20133.1) and prolactin\u2010elevating antipsychotics (\n                      <jats:styled-content style=\"fixed-case\">SIR<\/jats:styled-content>\n                      \u00a0=\u00a02.0, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      \u00a0=\u00a01.9\u20132.2).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In people aged 60 and older in Norway, those who took an antipsychotic drug had twice the risk of sustaining a hip fracture during exposure than during nonexposure. Although confounding by indication, comorbidity, or other drugs used cannot be excluded, this association is relevant for clinical practice because hip fracture and antipsychotic drug use are prevalent in vulnerable older individuals. Clinical studies examining mechanisms or causality of the observed association between antipsychotic drug use and excess risk of hip fracture are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jgs.14162","type":"journal-article","created":{"date-parts":[[2016,6,20]],"date-time":"2016-06-20T03:29:27Z","timestamp":1466393367000},"page":"1203-1209","source":"Crossref","is-referenced-by-count":23,"title":["Antipsychotic Drugs and Risk of Hip Fracture in People Aged 60 and Older in Norway"],"prefix":"10.1111","volume":"64","author":[{"given":"Marit S.","family":"Bakken","sequence":"first","affiliation":[{"name":"Department of Global Public Health and Primary Care Faculty of Medicine and Dentistry University of Bergen Bergen Norway"},{"name":"Kavli Research Centre for Geriatrics and Dementia Haraldsplass Deaconess Hospital Bergen Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Schj\u00f8tt","sequence":"additional","affiliation":[{"name":"Department of Clinical Science Faculty of Medicine and Dentistry University of Bergen Bergen Norway"},{"name":"Section\u00a0of Clinical Pharmacology Laboratory of Clinical Biochemistry Haukeland University Hospital Bergen Norway"},{"name":"Regional Medicines Information and Pharmacovigilance Centre Haukeland University Hospital Bergen Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Engeland","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Primary Care Faculty of Medicine and Dentistry University of Bergen Bergen Norway"},{"name":"Department of Pharmacoepidemiology Norwegian Institute of Public Health Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars B.","family":"Enges\u00e6ter","sequence":"additional","affiliation":[{"name":"Department of Clinical Science Faculty of Medicine and Dentistry University of Bergen Bergen Norway"},{"name":"Norwegian Arthroplasty Registry Department of Orthopaedics and Department of Clinical Medicine Haukeland University Hospital Bergen Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Ruths","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Primary Care Faculty of Medicine and Dentistry University of Bergen Bergen Norway"},{"name":"Research Unit for General Practice Uni Research Health Bergen Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50455.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/17453674.2010.492763"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.epirev.a017956"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1999.tb01898.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182075587"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0861"},{"key":"e_1_2_6_8_1","first-page":"159","article-title":"The adverse skeletal effects of selective serotonin reuptake inhibitors","volume":"27","author":"Tsapakis EM","year":"2011","journal-title":"Eur Psychiatry"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-012-0121-4"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.560112"},{"key":"e_1_2_6_11_1","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index [on\u2010line]. Available athttp:\/\/www.whocc.no\/atc_ddd_index\/Accessed June 16 2014."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbt034"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1360"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/11588470-000000000-00000"},{"key":"e_1_2_6_15_1","first-page":"CD007726","article-title":"Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia","volume":"3","author":"Declercq T","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610211000718"},{"key":"#cr-split#-e_1_2_6_17_1.1","unstructured":"Norwegian Institute of Public Health.The Norwegian Prescription Database 2009-2013 (Legemiddelstatstikk 2014:2"},{"key":"#cr-split#-e_1_2_6_17_1.2","unstructured":"Reseptregisteret 2009-2013).Oslo Norway:Norwegian Institute of Public Health 2014."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12043"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","unstructured":"dervanPuttenMJ WetzelsRB BorHet\u00a0al.Antipsychotic drug prescription rates among Dutch nursing homes: The influence of patient characteristics and the dementia special care unit.Aging Ment Health2014;18:828\u2013832.","DOI":"10.1080\/13607863.2014.884537"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.24095\/hpcdp.34.2\/3.08","article-title":"A comprehensive profile of the sociodemographic, psychosocial and health characteristics of Ontario home care clients with dementia","volume":"34","author":"Vu M","year":"2014","journal-title":"Chronic Dis In Can"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/08946560902779860"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.3902"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-72"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12216"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn009"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04307yel"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4002066"},{"key":"e_1_2_6_28_1","first-page":"605","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review","volume":"28","author":"Peuskens J","year":"2014","journal-title":"CNS Drugs"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-9209com"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.10.141"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075783"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125313487548"},{"key":"e_1_2_6_33_1","first-page":"129","article-title":"Establishment of the nationwide Norwegian Prescription Database","volume":"18","author":"Furu K","year":"2008","journal-title":"Nor J Epidemiol"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/17453670810016588"},{"key":"e_1_2_6_35_1","unstructured":"The Norwegian Central Population Register [on\u2010line]. Available athttp:\/\/www.folkeregistret.no\/Accessed July 11 2015."},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2011.01697.x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2012.03.002"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107088435"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0623-x"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.2165\/11315960-000000000-00000"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2007.03.009"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.07.005"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-008-0826-5"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.106.023671"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2008.02.004"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.915"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.04.003"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgs.14162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgs.14162","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgs.14162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T15:53:13Z","timestamp":1762185193000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/jgs.14162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/jgs.14162"],"URL":"https:\/\/doi.org\/10.1111\/jgs.14162","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}